借力推动前列腺癌 CAR-T 细胞治疗进展
Piggybacking toward Progress for CAR T-Cell Therapy in Prostate Cancer.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
去势抵抗性前列腺癌中的新型药物与临床试验：2023 ASCO-GU 肿瘤研讨会最新进展
英文原题：Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium.
查看英文原题
Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
2023年美国临床肿瘤学会-泌尿生殖系统（ASCO-GU）癌症研讨会上报告了许多针对去势抵抗性前列腺癌（CRPC）的新型有效治疗药物和临床试验。值得注意的是，放射性核素药物偶联物（RDC），特别是177Lu/111In-J591和225Ac-J591，在治疗CRPC患者中表现出增强的治疗疗效。此外，CRPC的有前景的治疗方法包括在罕见肿瘤中双重抗细胞毒性T淋巴细胞相关蛋白4（CTLA-4）和抗程序性死亡-1（PD-1）阻断（DART）-Lorigerlimab、前列腺干细胞抗原（PSCA）导向的嵌合抗原受体（CAR）-T细胞免疫疗法-BPX-601，以及蛋白激酶抑制剂（AKTi）-CAPltello-280。我们总结了2023年ASCO-GU癌症研讨会上提出的最新CRPC治疗策略，以及CRPC临床试验的最新进展。
展开英文摘要原文
Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium.
Notably, radionuclide drug conjugates (RDC), specifically 177Lu/111In-J591 and 225Ac-J591, exhibited enhanced therapeutic efficacy in treating patients with CRPC.
Furthermore, promising treatment approaches for CRPC included dual anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) blockade in rare tumors (DART)-Lorigerlimab, prostate stem cell antigen (PSCA)-directed chimeric antigen receptor (CAR)-T cell immunotherapy-BPX-601, and protein kinase inhibitor (AKTi)-CAPltello-280.
We have summarized the latest CRPC treatment strategies presented at the 2023 ASCO-GU Cancers Symposium, along with recent advances in CRPC clinical trials.
论文信息
- 作者
- Jiang Y、Wu S、Li R、Yu J、Zheng J、Li Z、Li M、Xin K
- 第一作者单位
- Department of Urology, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China.China
- 通讯作者单位
- Department of Urology, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China. chenxn@cmu.edu.cn.China
- 文献类型
- 读者来信
- 期刊
- Experimental hematology & oncology2023 Aug 1
- 原文标识
- PubMed 37528464 · DOI 10.1186/s40164-023-00430-1
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →